Sign in
TerminatedPhase 3

Cromolyn Sodium for Treatment of COVID-19 Pneumonia

Key facts

Who runs it
Texas Tech University Health Sciences Center, El Paso
Where
El Paso, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 3
People taking part
22 people enrolled
Started
15 Nov 2021
Ended
23 May 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Cromolyn Sodium
  • Placebo
Record updated
18 November 2024
Why it stopped
slow enrollment

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • COVID-19 symptoms (fever, cough, sore throat, malaise, headache, muscle pain, dyspnea at rest or with exertion, confusion, or respiratory distress),
  • diagnosis of COVID-19 pneumonia with an admission chest x-ray demonstrating multilobar ground glass infiltrates consistent with COVID-19 pneumonia
  • room air estimated PaO2/FiO2 ratio between 150 -280
  • must correct to a pulse oximetry of 90% or better using no more than 5 liters of low flow supplemental oxygen
  • must be enrolled within 24 hours of hospital admission

Who cannot take part

  • currently on oxygen supplementation greater than low flow nasal cannula (including home oxygen therapy; CPAP for obstructive sleep apnea is not an exclusion)
  • immunocompromised due to current use of immunosuppressive drugs or chemotherapy, have a history of HIV/organ transplant/ active hepatitis B or C, or are on hemodialysis or peritoneal dialysis
  • experiencing shock (on vasopressors) or multiple organ dysfunction or failure
  • are co-infected with influenza A or B
  • history of DVT or PE within last 12 weeks
  • allergic to cromolyn sodium
  • have DNR status or not expected to survive >7 days
  • currently pregnant or nursing
  • participating in another therapeutic trial

Where in United States

  • University Medical Center of El PasoEl Paso, United States

About the trial

What the trial wants to find out

The study hypothesis is that cromolyn, when combined with standard COVID-19 treatment, will improve patient symptoms and reduce the number of days to improved quality of life.

Read full original descriptionShow less

Investigators will study the effects of adding cromolyn to the standard treatment of hospitalized patients with COVID-19 pneumonia and who require supplemental oxygen. Cromolyn will be administered as a nebulized treatment four times a day for four days followed by intranasal administration for two weeks. Investigators may also screen for biomarkers that could indicate inflammatory responses and treatment-induced improvement.

Participants will receive either study drug or placebo which will be administered by nebulization for 4 days followed by 14 days of intranasal administration. Participants will be followed while in the hospital and then as outpatients up to day 21 following randomization.

The 2 groups in the trial

  • CromolynTreatment being tested

    2mL of 1% cromolyn sodium solution delivered via nebulizer 4 times a day for 4 days followed by 4% cromolyn solution administered intranasally 4 times per day for 14 days

    Treatment: Cromolyn Sodium

  • PlaceboPlacebo, for comparison

    2-3mL of normal saline delivered via nebulizer 4 times a day for 4 days followed by intranasal administration of normal saline 4 times per day for 14 days

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
18 November 2024